#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Internal Medicine / 2018 - 9

The heart transplantation

Czech version

Authors: Lenka Špinarová 1;  Jindřich Špinar 2;  Jiří Vítovec 1
Authors‘ workplace: I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně 1;  Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice 2
Published in: Vnitř Lék 2018; 64(9): 860-866
Category: Reviews

Overview

The article reviews history, indication and follow-up after heart transplantation, including the mechanical assist devices. Various complications of posttransplant follow-up are mentioned, e.g. rejection, infection, vasculopathy, meta­bolic disorders, hypertension or malignities. Pharmacotherapy used for immunosuppression is discussed. Heart transplantation improves the prognosis of patients with previous heart failure and also their quality of life. Key words: heart transplantation – immunosuppression – mechanical assist devices – rejection – terminal heart failure

Sources
  1. Barnard CN. A human cardiac transplant. S Afr Med J 1967; 41(48): 1271–1274.
  2. Černý J. Historie srdečních transplantací – krátké zamyšlení. Vnitř Lék 2000; 46(11): 741–742.
  3. Hosain N, Amin F, Leprince P. Christian Cabrol MD: A Tribute to pioneer cardiac surgeon Christian Cabrol 1 year after his death, on the 50th Anniversary of the First European Human Heart Transplantation that he performed in 1968. Eur Heart J 2018; 39(19): 1661–1671. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehy195>.
  4. Fabián J. Z historie slovenskej transplantológie srdca. Cardiol 2000; 9(4): 200–201.
  5. Lund LH, Khush KK, Cherikh WS et al. The Registry of the International Society for Heart and Lung Transplantation. Tirty-fourth Adult Heart Transplantation Report-2017; Focus Teme: Allograft ischemic time. J Heart Lung Transplant 2017; 36(10): 1037–1046. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2017.07.019>.
  6. Kočandrle V, Fabián J, Firt P. Transplantace srdce. Čas Lék čes 1984; 123(47): 1425–1429.
  7. Ponikowski P, Voors AA, Anker SD. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>.
  8. Špinar J, Hradec J, Špinarová L et al. Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016. Připraven Českou kardiologickou společností. Cor Vasa 2016; 58(5): 455–494.
  9. Crespo-Leiro MG, Metra M, Lund LH et al. Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1236>.
  10. Ammirati E, Oliva F, Cannata A et al. Current indication for heart transplantation and left ventricular asisst device: a practical point of view. Eur J Int Med 2014; 25(5): 422–429. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejim.2014.02.006>.
  11. Rothenburger M, Zuckermann A, Bara C et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Conference. J Heart and Lung Transpl 2007; 26(4): 305–311. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2007.01.010>.
  12. Costanzo MR, Dipchand A, Starling R et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29(8): 914–956. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2010.05.034>.
  13. Špinarová L, Vítovec J. Kombinační imunosupresivní léčba. Kardiol Rev a Int Med 2014; 16(6): 472–474.
  14. Špinarová L. Transplantace srdce – minulost, současnost a výhled do budoucna. Vnitř Lék 2010; 56(8): 884–888.
  15. Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. Heart rejection Study Group. The International Society for Heart and Lung Transplantation. J Heart Transplant 1990; 9(6): 587–593.
  16. Stewart S, Winter GL, Fischbein MC et al. Revision of the 1990 Working Formulation for the standardization of nomenclature in the Diagnosis of Heart rejection. J Heart Lung Transplant 2005; 24(11): 1710–1720. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2005.03.019>.
  17. Špinarová L. Sledování pacienta po transplantaci srdce. In: Táborský M, Kautzner J, Linhart A. Kardiologie. 2. ed. Mladá fronta: Praha 2018: 1382–1390. ISBN 978–80–204–4812–5. ISBN 978–80–204–4813–2. ISBN 978–80–204–4900–9.
  18. Špinarová L, Hude P, Krejčí J et al. Farmakoterapie hypertenze po transplantaci srdce. Vnitř Lék 2012; 58(7–8): 608–611.
  19. Rothenburger M, Zuckermann A, Bara C et al. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Conference. J Heart and Lung Transplant 2007; 26(4): 305–311. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2007.01.010>.
  20. Špinarová L, Vítovec J. Statiny a srdeční transplantace. Remedia 2005; 15(2): 154–157.
  21. Skalická B, Kubánek M, Málek I et al. Conversion to tacrolimus and atorvastatin in cyclosporine- treated heart transplant recipients with dyslipidemia refractory to fluvastatin. J Heart Lung Transplant 2009; 28(6): 598–604. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2009.03.014>.
  22. Peled Y, Lavee J, Raichlin E et al. Metformin therapy reduces the risk of malignancy after heart transplantation. J Heart Lung Transplant 2017; 36(12): 1350–1357. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2017.06.009>.
  23. Nikolaidis L, Shah S, McGonagle F et al. Diabetes mellitus following heart transplantation. J Heart Lung Transplant 2010; 29(2 Suppl): S154. Dostupné z DOI: <https://doi.org/10.1016/j.healun.2009.11.485>.
  24. Fort AC, Gavira JJ, Alegria-Barrero E et al. Prevalence of metabolic syndrome in heart transplant patients: Role of previous cardiopathy and years since the procedure – the TRACA study. J Heart Lung Transplant 2006; 25(10): 1192–1198. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2006.06.012>.
  25. Špinarová L, Lidinský P, Krejčí J et al. Metabolický profil pacienta po transplantaci srdce. Cor Vasa 2013; 55(4): 423–427.
  26. Sanchez-Lazaro I, Sanchez-Gomez JM, Martinez-Dolz L et al. Is metabolic syndrome important in the development of cardiac allograft vasculopathy in heart transplantation patients? J Heart Lung Transplant 2012; 31(4 Suppl): S94. Dostupné z DOI: <https://doi.org/10.1016/j.healun.2012.01.267>.
  27. Špinarová L, Hude P, Krejčí J et al. Osud pacientů přežívajících deset let po transplantaci srdce se zřetelem k výskytu maligního onemocnění. Cor Vasa 2009; 51(6): 415–418.
  28. Roithmaier S, Haydon AM, Loi S et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007; 26(8): 845–849. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2007.05.019>.
Labels
Diabetology Endocrinology Internal medicine Cardiology
Pathophysiology, causes and epidemiology of chronic heart failure
What we know about epidemiology of heart failure in Slovakia and globally
Diagnosis of heart failure: the new classification of heart failure
Pharmacological therapy for chronic heart failure
Comorbidities in heart failure
Arrhythmias and conductance disturbances and heart failure
Otto Kahler and his family (on the 125th anniversary of his death): I. Ancestors
Outpatient treatment of proximal deep vein thrombosis
Article was published in

Internal Medicine

Issue 9
2018 Issue 9
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#